STMC-103H
BiologicalSTMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria
NCT Number: NCT05003804
This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-103H in neonates and infants at risk for developing allergic disease (Type 1 hypersensitivity). Subjects will be enrolled in a three-part sequential approach. Participants in the safety-run portion of the study (Part A1: 1 year to <6 years of age and A2: 1 month to <12 months of age) will receive 28 days of treatment with STMC-103H or placebo, followed by 28 days of follow-up. A Data and Safety Monitoring Committee (DSMC) will review safety data after all patients in each part complete 28 days of therapy prior to enrolling the next part. After A2, Part B will enroll 224 patients for 336 days of treatment with STMC-103H or placebo, followed by 336 days of follow-up. Stool, blood, and optional samples will be collected in Parts A2 and part B. Primary safety endpoints are frequency, type and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs), as well as findings on physical exams, vitals, and safety laboratories. The primary efficacy endpoint is incidence of physician-diagnosed atopic dermatitis at day 336.
Looking for future studies?
Notify Me0 day–14 day
All sexes
Interventional
Phase 1 / Phase 2
The Children's Hospital at Westmead, Westmead, New South Wales, Australia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Part A1 Only
Inclusion criteria
1-4 for all parts plus:
5 (A1). Subject is between 1 year and < 6 years old at the time of enrollment
Part A2 Only
Inclusion criteria
1-4 for all parts plus:
5 (A2). Subject is between 28 days and < 12 months of life at the time of enrollment 6 (A2). Subject's parent(s)/legal representative(s) do not plan to give probiotics (including infant formula that contain probiotics) to the subject during the trial
Part B Only
Inclusion criteria
1-4 for all parts plus:
5 (B). Subject is ≤ 14 days of life at the time of enrollment. Sites should make every effort to enroll newborns as soon as possible after birth.
6 (B). Subject has a birthweight ≥ 2.5 kg and ≤ 4.5 kg 7 (B). Subject's parent(s)/legal representative(s) do not plan to give probiotics (including infant formula that contain probiotics) to the subject from the time of birth to the end of the trial.
Exclusion criteria
Part B Only
Exclusion criteria
1-5 for all parts plus:
6 (B). Subject was born at < 35 weeks' gestation 7 (B). Biological maternal medical condition during the pregnancy that, in the opinion of the PI, may put the subject at risk because of participation in the study. (Maternal antibiotics during the time of delivery should not be considered exclusionary.)
STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria
Powder containing excipients found in STMC-103H: magnesium stearate, mannitol and silicon dioxide.
Time frame: Through 56 days of study
Frequency, type, and severity of AEs and SAEs, including AEs of special interest (AESI) as in Appendix 9 (Adverse Events of Special Interest) and Appendix 10 (Adverse Event Grading Scale)
Time frame: Through 672 days of study
Frequency, type and severity of AEs, SAEs, and AESIs as in Appendix 9 (Adverse Events of Special Interest) and Appendix 10 (Adverse Event Grading Scale), as well as clinically significant findings on physical examinations including growth (length, weight, height and head circumference) and vital signs (RR, HR, and temperature); clinical safety laboratories including complete blood count with manual differential and blood chemistry
Time frame: Day 336
Incidence of physician-diagnosed atopic dermatitis at 336 days in STMC-103H-treated subjects compared to placebo
Time frame: At days 168 and 672
Incidence of physician-diagnosed atopic dermatitis
Time frame: At days 168, 336 and 672
Proportion of subjects who develop any atopic disease (atopic dermatitis, food allergy, allergic rhinitis/conjunctivitis, asthma)
Time frame: At days 168, 336, and 672
Incidence of sensitization to food and aeroallergen as measured by specific serum IgE levels
Time frame: At days 168, 336, and 672
Incidence of physician-diagnosed food allergy, allergic rhinitis/conjunctivitis, urticaria and wheezing illnesses/asthma using physician assessment, Allergic Disease Assessment and Diagnosis questionnaire, and Allergic Disease Diagnostic Criteria & Severity Evaluation
Time frame: Through 672 days of study
Time to atopic dermatitis diagnosis by physician assessment
Time frame: Through 672 days of study
Time to first wheezing episode by physician assessment
Time frame: At days 168, 336 and 672
Severity of atopic dermatitis by IGAxBSA assessment
Time frame: At days 168, 336 and 672
Severity of atopic dermatitis by SCORAD assessment
Time frame: At days 68, 336, and 672 days
Severity of wheezing illness/asthma by Wheezing Severity Assessment
Time frame: Through 672 days of study
Concomitant medications prescribed/used for allergic symptoms or diagnosis and use of rescue medications for atopic dermatitis and wheezing/asthma
Time frame: At days 168, 336, and 672
Total serum IgE levels
Time frame: At day 336
Peripheral eosinophil counts by automated differential
Time frame: At day 336
Mean fecal concentration of 12,13-diHOME measured in stool sample in STMC-103H arm as compared to placebo arm
Siolta Therapeutics, Inc.
Industry
A Phase 1b/2, Randomized, Double-blind, Placebo-controlled, Multi-center Study of STMC-103H in Neonates and Infants at Risk for Developing Allergic Disease
Acronym: adored
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05613062
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hong Kong
View Trial DetailsNCT05633355
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Phoenix, Arizona, United States
View Trial DetailsNCT05899816
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Scottsdale, Arizona, United States
View Trial DetailsNCT05398445
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial Details